Aarti Drugs Limited Reports Audited Standalone and Consolidated Earnings Results for the First Quarter Ended June 30, 2018
August 14, 2018 at 08:17 am EDT
Share
Aarti Drugs Limited reported audited standalone and consolidated earnings results for the first quarter ended June 30, 2018. For the quarter, on standalone basis, the company reported revenue from operations of INR 3,515.5 million against INR 2,482.6 million a year ago. Profit before exceptional items and tax was INR 323.9 million against INR 155.2 million a year ago. Profit before tax was INR 323.9 million against INR 155.2 million a year ago. Profit from continuing operations was INR 223.9 million against INR 105.7 million a year ago. Profit was INR 223.9 million or INR 9.40 per basic and diluted share against INR 105.7 million or INR 4.43 per basic and diluted share a year ago.
For the quarter, on consolidated basis, the company reported revenue from operations of INR 3,742.9 million against INR 2.772.0 million a year ago. Profit before exceptional items and tax was INR 337.2 million against INR 167.2 million a year ago. Profit before tax was INR 337.2 million against INR 167.2 million a year ago. Profit from continuing operations was INR 233.7 million against INR 113.8 million a year ago. Profit was INR 233.7 million or INR 9.82 per basic and diluted share against INR 113.8 million or INR 4.77 per basic and diluted share a year ago. EBITDA was INR 535.3 million, up by 57% and consolidated profit after tax was INR 233.7 million, up by 105.5%. However, the growth numbers are higher as June 2017 quarter was badly impacted due to GST transitioning.
Aarti Drugs Limited is an India-based company that is engaged in the manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates, specialty chemicals and formulations. The Company operates through pharmaceuticals segment. The Company's APIs products include ciprofloxacin hydrochloride, metronidazole, metformin HCL, ketoconazole and ofloxacin, among others. Its specialty chemicals products include benzene sulphonyl chloride and methyl nicotinate, among others. Its pharma intermediates products include tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, raloxifene and zolpidem. Its products under development include itraconazole, fluconazole, dabigatran, ticagrelor, sitagliptin and alpha lipoic acid. The Company's subsidiaries include Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SPA.